Results 161 to 170 of about 5,449,771 (353)
Health Report [PDF]
, 2009 This Plan for Health is an unusual undertaking in two respects. It is part of the Go To 2040 regional master plan along with other human services components that have, historically, been outside the purview of planners, who are usually more concerned ...Amanda LeBreche, D. Patrick Lenihan, Richard Sewell +2 morecore Early metastasis is characterized by Gr1+ cell dysregulation and is inhibited by immunomodulatory nanoparticles
Molecular Oncology, EarlyView.Breast cancer metastasis is associated with myeloid cell dysregulation and the lung‐specific accumulation of tumor‐supportive Gr1+ cells. Gr1+ cells support metastasis, in part, through a CHI3L1‐mediated mechanism, which can be targeted and inhibited with cargo‐free, polymeric nanoparticles.Jeffrey A. Ma, Sophia M. Orbach, Kate V. Griffin, Kathryn Kang, Yining Zhang, Rebecca S. Pereles, Ian A. Schrack, Guillermo Escalona, Jacqueline S. Jeruss, Lonnie D. Shea +9 morewiley +1 more sourceDetecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data
Molecular Oncology, EarlyView.This study develops a semi‐supervised classifier integrating multi‐genomic data (1404 training/5893 validation samples) to improve homologous recombination deficiency (HRD) detection in breast cancer. Our method demonstrates prognostic value and predicts chemotherapy/PARP inhibitor sensitivity in HRD+ tumours.Rong Zhu, Katherine Eason, Suet‐Feung Chin, Paul A. W. Edwards, Raquel Manzano Garcia, Richard Moulange, Jia Wern Pan, Soo Hwang Teo, Sach Mukherjee, Maurizio Callari, Carlos Caldas, Stephen‐John Sammut, Oscar M. Rueda +12 morewiley +1 more sourceCall for improvement in medical school training in genetics: results of a national survey
Genetics in Medicine, 2021 R. Haspel, J. Genzen, Jay Wagner, Karen Fong, Richard L. Rebecca Patricia V. Hana James B. Leah W. Loren Haspel Wilcox Adem Anderson Atkinson Burke Joseph , R. Haspel, Rebecca L. Wilcox, Patricia V Adem, H. Anderson, James B. Atkinson, L. Burke, Loren J. Joseph, R. Legallo, Madelyn Lew, C. Lockwood, Rizwan Naeem, Hasan Rizvi, Julian Sanz Ortega, Kate P Shane-Carson, Marc Sobel, Eric Suarez, L. Tafe, Jason Wang, Rebecca L. Wilcox +23 moresemanticscholar +1 more sourceEvaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8‐year study of 10 754 patients in Turkey
Molecular Oncology, EarlyView.This nationwide study evaluated KRAS and NRAS mutations in 10 754 Turkish patients with metastatic colorectal cancer. The results revealed a mutation frequency of 51.1%, with 46.6% having KRAS mutations, 4.5% having NRAS mutations, and 48.5% being wild‐type for both.Gozde Kavgaci, Izzet Akiva, Yavuz Hakan Ozon, Hakan Berkil, Huseyin Karadayi, Omer Dizdar, Suayib Yalcin +6 morewiley +1 more sourceRecommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics
Genetics in Medicine, 2016 Sarah S. Kalia, Kathy Adelman, Sherri Bale, Wendy K Chung, Christine M. Eng, James P. Evans, Gail E. Herman, Sophia B. Hufnagel, Teri E Klein, Bruce R. Korf, Kent D. McKelvey, K. Ormond, C. Sue Richards, C. Vlangos, Michael S. Watson, Christa L. Martin, David T. Miller +16 moresemanticscholar +1 more source